Journal
CLINICAL OPHTHALMOLOGY
Volume 8, Issue -, Pages 1675-1679Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OPTH.S68243
Keywords
anti-VEGF therapy; choroideremia; choroidal neovascular membrane; chorioretinal degeneration; hereditary choroidal dystrophy; intravitreal bevacizumab injection
Categories
Funding
- Research to Prevent Blindness (New York, NY, USA)
Ask authors/readers for more resources
Purpose: To report a rare case of central vision loss in a patient with choroideremia. Patients and methods: A retrospective, interventional case report. Results: A 13-year-old male with history of choroideremia presented with subacute loss of central acuity in his left eye. Examination and diagnostic testing revealed subretinal fibrosis secondary to a choroidal neovascular membrane (CNVM). A trial of anti-vascular endothelial growth factor (VEGF) therapy with the injection of intravitreal bevacizumab was attempted. Mild improvements in acuity and anatomy were noted. Conclusion: Choroideremia is a rare hereditary choroidal dystrophy that predominantly affects males in the first and second decades of life. Visual acuity is usually spared until later in life. CNVM is a rare manifestation of choroideremia with only a handful of case reports presented in the literature. This case is unique in that it is the first reported case that received treatment with intravitreal anti-VEGF therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available